A 6-week, Randomised, Multi-centre, Open-labelled, Parallel Group, Exploratory Trial to Investigate the Safety of SIBA Once Daily + NovoRapid (R) Compared to Insulin Detemir Once Daily + NovoRapid®, All in a Basal-bolus Regimen in Subjects With Type 1 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin detemir
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 20 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Feb 2009 New trial record